A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Administered SHR-1819 in Healthy Subjects
Latest Information Update: 13 Jul 2022
At a glance
- Drugs SHR-1819 (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Atridia
- 11 Jul 2022 Status changed from recruiting to completed.
- 29 Dec 2021 Status changed from not yet recruiting to recruiting.
- 29 Sep 2020 New trial record